Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$24.41 -0.4%	$26.77	$22.64 ▼ $53.96	$1.16B	0.79	465,504 shs	460,186 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
IOVA Iovance Biotherapeutics	$3.59 +0.8%	$3.61	$2.70 ▼ $14.23	$1.18B	1.05	7.61 million shs	7.07 million shs
MBX MBX Biosciences	$10.49 +6.3%	$8.32	$4.81 ▼ $27.50	$350.62M	N/A	250,124 shs	345,746 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+0.37%	+2.38%	-13.82%	-32.73%	-41.69%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+114.44%
IOVA Iovance Biotherapeutics	-1.39%	+10.90%	0.00%	-41.35%	-70.41%
MBX MBX Biosciences	+5.56%	+14.24%	+27.19%	-3.89%	+986,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.5045 of 5 stars	3.0	3.0	0.0	3.7	3.6	4.2	1.3
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	4.5529 of 5 stars	4.4	3.0	0.0	4.2	2.2	2.5	0.6
MBX MBX Biosciences	2.4908 of 5 stars	3.5	0.0	0.0	0.0	3.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.00	Hold	$43.50	78.21% Upside
CALT Calliditas Therapeutics AB (publ)	2.00	Hold	$39.25	-1.88% Downside
IOVA Iovance Biotherapeutics	2.89	Moderate Buy	$18.22	407.58% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	257.48% Upside

Current Analyst Ratings Breakdown

Latest MBX, CALT, IOVA, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
4/14/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$22.00 ➝ $5.00
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/10/2025	MBX MBX Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
4/10/2025	MBX MBX Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $44.00
4/10/2025	MBX MBX Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$38.00
3/21/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $32.00
3/3/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $15.00
3/3/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
3/3/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $30.00
2/28/2025	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.58	$3.40 per share	7.17	$13.35 per share	1.83
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
IOVA Iovance Biotherapeutics	$164.07M	7.17	N/A	N/A	$2.28 per share	1.57
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$137.54M	$3.06	8.14	7.42	2.19	21.80%	26.44%	11.89%	5/6/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
IOVA Iovance Biotherapeutics	-$444.04M	-$1.30	N/A	N/A	N/A	-451.25%	-58.43%	-45.48%	5/8/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest MBX, CALT, IOVA, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	AMPH Amphastar Pharmaceuticals	$0.66	N/A	N/A	N/A	$173.29 million	N/A
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	N/A	N/A	N/A	$83.40 million	N/A
2/27/2025	Q4 2024	IOVA Iovance Biotherapeutics	-$0.26	-$0.26	N/A	-$0.26	$72.17 million	$73.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
IOVA Iovance Biotherapeutics	N/A	4.22	3.90
MBX MBX Biosciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
CALT Calliditas Therapeutics AB (publ)	2.83%
IOVA Iovance Biotherapeutics	77.03%
MBX MBX Biosciences	N/A

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.10%
CALT Calliditas Therapeutics AB (publ)	2.20%
IOVA Iovance Biotherapeutics	12.10%
MBX MBX Biosciences	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.50 million	35.05 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
IOVA Iovance Biotherapeutics	500	327.88 million	267.90 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A

MBX, CALT, IOVA, and AMPH Headlines

Recent News About These Companies

MBX Biosciences, Inc. (NYSE:MBX) Shares Purchased by Geode Capital Management LLC

April 28 at 3:24 AM | marketbeat.com

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

April 23, 2025 | finance.yahoo.com

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

April 22, 2025 | globenewswire.com

Ascendis Pharma initiated with an Outperform at RBC Capital

April 16, 2025 | markets.businessinsider.com

Franklin Resources Inc. Cuts Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)

April 12, 2025 | marketbeat.com

JMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform Recommendation

April 11, 2025 | msn.com

Ora H. Pescovitz Buys 7,693 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

April 11, 2025 | insidertrades.com

MBX Biosciences initiated with an Outperform at Citizens JMP

April 10, 2025 | markets.businessinsider.com

MBX Biosciences adds biotech veteran to board

April 9, 2025 | uk.investing.com

MBX Biosciences appoints Steve Hoerter to board of directors

April 8, 2025 | markets.businessinsider.com

MBX Biosciences Appoints Steve Hoerter to Board

April 7, 2025 | tipranks.com

Charles Schwab Investment Management Inc. Invests $1.72 Million in MBX Biosciences, Inc. (NYSE:MBX)

March 30, 2025 | marketbeat.com

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 26, 2025 | globenewswire.com

MBX Biosciences reports Q4 EPS (47c), consensus (59c)

March 17, 2025 | markets.businessinsider.com

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

March 17, 2025 | globenewswire.com

Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide

March 13, 2025 | finance.yahoo.com

MBX Biosciences announces additions to its leadership team

March 6, 2025 | markets.businessinsider.com

MBX Biosciences Announces Additions to Leadership Team

March 5, 2025 | globenewswire.com

MBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109

March 3, 2025 | markets.businessinsider.com

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

March 3, 2025 | globenewswire.com

MBX Biosciences unveils new, long-acting antiobesity asset

February 22, 2025 | bioworld.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX, CALT, IOVA, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$24.41 -0.09 (-0.37%)

As of 04:00 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 04/28/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Iovance Biotherapeutics NASDAQ:IOVA

$3.59 +0.03 (+0.84%)

As of 04:00 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

MBX Biosciences NYSE:MBX

$10.49 +0.62 (+6.28%)

As of 04:00 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time